Juliette Berangere Audet - Apr 1, 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Business Officer
Signature
/s/ Louise Kooij by Power of Attorney from Juliette Berangere Audet
Stock symbol
NAMS
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/2/2024, 04:30 PM
Previous filing
Dec 29, 2023
Next filing
Sep 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +250K $0.00 250K Apr 1, 2024 Ordinary Shares 250K $21.37 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person resigned from the Issuer's board of directors, effective April 1, 2024, in light of her appointment as the Issuer's Chief Business Officer ("CBO"). The option reported herein was granted in connection with the Reporting Person's appointment as CBO.
F2 25% of the shares underlying the option will vest on April 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.